Document is current

Any future updates will be listed below

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

Crossref DOI link: https://doi.org/10.1007/s12325-021-02025-w

Published Online: 2022-01-24

Published Print: 2022-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark